Literature DB >> 24852670

Detection of asymptomatic cranial neuropathies in patients with systemic lupus erythematosus and their relation to antiribosomal P antibody levels and disease activity.

Wafaa Gaber1, Yasser Ezzat, Neveen M El Fayoumy, Hanan Helmy, Abeer M Mohey.   

Abstract

The objectives of this study are to assess the risk of asymptomatic cranial neuropathy among patients with systemic lupus erythematosus (SLE) and find any association with disease activity and antiribosomal P antibodies. This study is a case-control study including 60 female patients and 30 healthy female controls. Disease activity was measured with the SLE disease activity index (SLEDAI). All patients were evaluated using evoked potentials, blink reflex, and levels of antiribosomal P antibodies. Patients with abnormal electrophysiological parameters had significantly higher levels of antiribosomal P antibodies (P = 0.034) and secondary antiphospholipid syndrome (P = 0.044). Antiribosomal P antibodies (odds ratio 5.4, 95 % confidence interval 1.002-1.03, P = 0.002) and presence of anti-DNA antibodies (odds ratio 1.01, 95 % confidence interval 1.2-24.8, P = 0.032) were independent risk factors for the presence of the abnormal electrophysiological parameters. Disease duration was positively correlated with wave 1 of the auditory brain reflex (P < 0.001) and a latency of the evoked blink reflex (component R1, P = 0.013). SLEDAI scores were positively correlated with latencies of the visually evoked potential (P100, P = 0.02), wave 1 of the auditory brain reflex (P < 0.001), and a latency of the evoked blink reflex (R2c, P = 0.005). Steroid dosage was negatively correlated with P100 latencies (P = 0.042) and components of the evoked blink reflex (R1, P = 0.042; R2i, P = 0.041; R2c, P < 0.001). Because abnormalities in the visually evoked potential and blink reflex were associated with antiribosomal P antibodies, they can be useful for detecting asymptomatic cranial neuropathy. Further studies on large number of patients should be done to determine any association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24852670     DOI: 10.1007/s10067-014-2679-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

Review 1.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.

Authors:  Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2007-01-26       Impact factor: 5.532

2.  Pattern electroretinography and visual evoked potentials in optic nerve diseases.

Authors:  Huban Atilla; Oya Tekeli; Kemal Ornek; Figen Batioglu; Atilla Halil Elhan; Teksin Eryilmaz
Journal:  J Clin Neurosci       Date:  2006-01       Impact factor: 1.961

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  Cranial nerve VI palsy as a rare initial presentation of systemic lupus erythematosus: case report and review of the literature.

Authors:  Z Saleh; J Menassa; O Abbas; S Atweh; T Arayssi
Journal:  Lupus       Date:  2009-10-30       Impact factor: 2.911

5.  Blotting patterns of IgG anti-(U1)RNP antibodies in mixed connective tissue disease.

Authors:  A Ghirardello; A Doria; P Vesco; E Vaccaro; C Bernardi; C Catani; U Fagiolo; P F Gambari
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations.

Authors:  F C Arnett; J D Reveille; H M Moutsopoulos; L Georgescu; K B Elkon
Journal:  Arthritis Rheum       Date:  1996-11

7.  Autoimmune sensorineural hearing loss.

Authors:  B F McCabe
Journal:  Ann Otol Rhinol Laryngol       Date:  1979 Sep-Oct       Impact factor: 1.547

8.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

Review 9.  Dilemmas in neuropsychiatric lupus.

Authors:  J A Kovacs; M B Urowitz; D D Gladman
Journal:  Rheum Dis Clin North Am       Date:  1993-11       Impact factor: 2.670

10.  Sensorineural hearing loss in lupus erythematosus.

Authors:  D D Caldarelli; J E Rejowski; J P Corey
Journal:  Am J Otol       Date:  1986-05
View more
  6 in total

Review 1.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Brainstem Reflexes in Systemic Lupus Erythematosus Patients Without Clinical Neurological Manifestations.

Authors:  Celal Salcini; Birgül Baştan; Gülin Sunter; Pınar Kahraman Koytak; Orhan Yilmaz; Tülin Tanridağ; Önder Us; Kayıhan Uluç
Journal:  Noro Psikiyatr Ars       Date:  2017-01-02       Impact factor: 1.339

3.  Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Qiuju Li; Li Su; Murray B Urowitz; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad A Zoma; Susan Manzi; Ola Nived; Andreas Jonsen; Munther A Khamashta; Graciela S Alarcón; Elisabet Svenungsson; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; Manuel Ramos-Casals; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2019-11-28       Impact factor: 10.995

Review 4.  Neurological Disease in Lupus: Toward a Personalized Medicine Approach.

Authors:  Sarah McGlasson; Stewart Wiseman; Joanna Wardlaw; Neeraj Dhaun; David P J Hunt
Journal:  Front Immunol       Date:  2018-06-06       Impact factor: 8.786

Review 5.  Psycho-rheumatic Integration in Systemic Lupus Erythematosus: An Insight into Antibodies Causing Neuropsychiatric Changes.

Authors:  Gouthami Nalakonda; Mimsa Islam; Vera E Chukwu; Ahmad Soliman; Rujina Munim; Inas Abukraa
Journal:  Cureus       Date:  2018-08-03

Review 6.  Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus.

Authors:  Minhui Wang; Ziqian Wang; Shangzhu Zhang; Yang Wu; Li Zhang; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.